We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement

Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement

Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement

Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Affitech AS and XOMA Ltd. have announced that they have signed an antibody collaboration and cross-license agreement for antibody-related technologies.

Under the agreement, Affitech receives a license to use XOMA's bacterial cell expression (BCE) technology for developing antibody products using Affitech's phagemid display-based Breitling antibody libraries, CBAS™ technology and the AffiscreeN™ high-throughput screening system.

Affitech also receives an option for the production of antibodies under XOMA's intellectual property.

The agreement allows XOMA to use Affitech's naive antibody library for target research and discovery purposes as well as the development and commercialization of selected antibodies.

In addition, Affitech has agreed to build patient-derived libraries for XOMA and discover new antibodies against XOMA targets exploiting Affitech's patient libraries, AffiscreeN™ system and its leading edge C.B.A.S.™(Cell-Based Antibody Screening) technology.

The agreement also provides for a release of Affitech and designated collaborators from any past activities using XOMA's antibody expression technology, and allows Affitech to use the XOMA technology in combination with its own technologies in future collaborations.

Dr. Martin Welschof, CEO of Affitech, said, "This agreement further underscores the importance of the Breitling IP family in the field of phage display-based antibody discovery area."

"We are delighted to be able to access XOMA's expression technology for our own product discovery and development as well as add this to our repertoire of technology and services for our current and future collaborators."

"We are especially pleased to enter into a broad collaboration with XOMA that potentially could involve multiple XOMA targets and our various antibody technologies including AffiscreeN™ and CBAS systems."

"We are pleased to enter into this human antibody phage display cross-licensing and collaboration agreement with Affitech," said Dr. Robert Gundel, Vice President, Scientific Corporate Development.

"Through the addition of Affitech's naive antibody library, XOMA now provides a single point of access to the world's largest collection (seven) of the leading commercially available antibody phage display libraries."

"In addition, custom antibody phage display libraries will be created using relevant patient populations to further enhance XOMA's extensive and unique antibody discovery and development platform."